Acute Interstitial Nephritis
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ overall reversibility
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Real-world reporting for this lesion
FAERS across all lesions →How disproportionately acute interstitial nephritis is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.
Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.
Documented in a profile with no reporting signal. Mostly expected: naming this lesion on a report can require a biopsy, or the agent has too few reports to divide.
A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.
The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.
AIN is systematically undercounted in FAERS — most true cases are filed under the generic “acute kidney injury” term rather than a distinct acute interstitial nephritis code, so the literature-only column is expected to run large here.
- CopanlisibPan-PI3K inhibitor · FAERS only48.08 (29.96–77.15) · n=18 Reporting signal.
- PemetrexedAntifolate · FAERS only13.28 (12.19–14.47) · n=541 Reporting signal.
- DostarlimabAnti-PD-1 antibody10.80 (7.34–15.90) · n=26 Reporting signal.
- PembrolizumabPD-1 checkpoint inhibitor10.75 (10.10–11.45) · n=1,063 Reporting signal.
- Dactinomycin (actinomycin D)Antitumor antibiotic · FAERS only9.70 (6.43–14.63) · n=23 Reporting signal.
- RelatlimabImmune checkpoint inhibitor (anti-LAG-3)9.03 (3.74–21.80) · n=5 Reporting signal, fragile (few reports).
- AmivantamabEGFR-MET bispecific antibody6.49 (4.38–9.63) · n=25 Reporting signal.
- IfosfamideOxazaphosphorine alkylator · FAERS only5.16 (4.31–6.18) · n=119 Reporting signal.
- NivolumabPD-1 checkpoint inhibitor5.03 (4.61–5.49) · n=523 Reporting signal.
- IpilimumabCTLA-4 checkpoint inhibitor4.71 (4.13–5.38) · n=221 Reporting signal.
- CarboplatinPlatinum agent · FAERS only4.65 (4.30–5.04) · n=636 Reporting signal.
- Loncastuximab tesirineAntibody-drug conjugate (CD19/PBD) · FAERS only4.52 (1.13–18.12) · n=2 Reporting signal, fragile (few reports).
- AtezolizumabAnti-PD-L1 antibody4.42 (3.79–5.14) · n=170 Reporting signal.
- Carmustine (BCNU)Nitrosourea alkylator · FAERS only3.93 (2.53–6.09) · n=20 Reporting signal.
- CemiplimabAnti-PD-1 antibody3.55 (1.77–7.12) · n=8 Reporting signal, fragile (few reports).
- Enfortumab vedotinAntibody-drug conjugate (Nectin-4/MMAE) · FAERS only3.54 (2.47–5.07) · n=30 Reporting signal.
- AvelumabAnti-PD-L1 antibody3.46 (2.05–5.85) · n=14 Reporting signal.
- ChlorambucilAlkylating agent (nitrogen mustard) · FAERS only3.29 (1.95–5.57) · n=14 Reporting signal.
- MogamulizumabAnti-CCR4 antibody · FAERS only3.24 (1.45–7.22) · n=6 Reporting signal, fragile (few reports).
- DurvalumabAnti-PD-L1 antibody2.92 (2.30–3.71) · n=68 Reporting signal.
- DabrafenibBRAF inhibitor2.36 (1.81–3.09) · n=54 Reporting signal.
- CobimetinibMEK inhibitor2.08 (1.12–3.87) · n=10 Reporting signal.
- TrametinibMEK inhibitor2.02 (1.54–2.64) · n=53 Reporting signal.
- EncorafenibBRAF inhibitor1.99 (1.31–3.03) · n=22 Reporting signal.
- TislelizumabPD-1 immune checkpoint inhibitor1.16 (0.63–2.16) · n=10 No reporting signal.
- BicalutamideNonsteroidal antiandrogen0.84 (0.50–1.42) · n=14 No reporting signal.
- Sacituzumab govitecanAntibody-drug conjugate (Trop-2/SN-38)0.76 (0.29–2.03) · n=4 No reporting signal.
- GefitinibEGFR TKI0.72 (0.34–1.51) · n=7 No reporting signal.
- IbrutinibBTK inhibitor0.43 (0.31–0.59) · n=38 No reporting signal.
reporting odds ratio (log) — no signal left of the dashed line at 1.0
No ratio — no AIN reports, or too few (count in brackets): Duvelisib, Idelalisib, Penpulimab, Procarbazine, Retifanlimab, Toripalimab
No ratio — under 50 FAERS reports in total: Cosibelimab, Ivonescimab, Sugemalimab
All 28 agents documented with AIN in the atlas are shown whether or not FAERS flags them, plus the 32 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). Class composites (BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib); Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)) are not asked of FAERS; their member agents are ranked individually. 46 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.
Management approach
Full framework →Per the ASON position statement: hold the drug, remove AIN cofactors, and treat with corticosteroids; biopsy when feasible to confirm and guide duration.
Drug-level levers
- Withhold the checkpoint inhibitor for grade ≥2 AKI.
- Discontinue concurrent AIN-culprit drugs (PPIs, NSAIDs, antibiotics).
- Permanently discontinue for grade 3–4 or recurrent immune-mediated nephritis.
- Rechallenge can be considered after recovery for lower-grade events — individualized, with close monitoring, given the recurrence risk.
Pharmacologic toolkit
- Corticosteroids — First line for grade ≥2: illustratively prednisone ~0.5–1 mg/kg/day (IV methylprednisolone for severe disease) with a slow taper over 4–6+ weeks.
- Steroid-refractory immunosuppression — For steroid-dependent or refractory AIN, agents such as mycophenolate mofetil or infliximab have been used.
When to biopsy
Favored when feasible to confirm AIN, exclude mimics, and guide steroid duration and rechallenge — but frequently deferred in cancer patients (thrombocytopenia, anticoagulation, single functioning kidney), so empiric corticosteroid treatment is common.
Monitoring
- · Creatinine before each cycle
- · Urinalysis (sterile pyuria, proteinuria)
- · Watch for concurrent immune-related adverse events
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
What the guidelines say
All guidelines →Society and consensus recommendations that speak to acute interstitial nephritis.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
Offending agents
Signature offenders
18Agents for which acute interstitial nephritis is the defining renal lesion.